About Us
Our team at Magnacor Inc, is at the forefront of cardiovascular innovation, leveraging decades of pioneering research to tackle some of the most critical unmet medical needs in healthcare. Led by two accomplished biotech researchers, Emil and Vadim, our team brings together a deep well of expertise in biotechnology, bolstered by an impressive portfolio of published research and patents. Their work has not only made significant contributions to the scientific community but also serves as a foundation for our unique approach to developing groundbreaking therapies for heart disease and related chronic inflammatory conditions.
Our Science / Technology
Purpose
To address the growing demand for novel therapies that target the underlying causes of cardiovascular disease (CVD), specifically the unmet need for treatments that prevent myocardial infarction (MI) and stroke.
Background
Atherosclerosis, a chronic inflammatory disease, remains a primary driver of heart attack and stroke. Despite strides in identifying risk factors and implementing tools like statins, cardiovascular deaths continue to rise globally. Notably, most cardiovascular events occur in patients with multiple risk factors who have not previously experienced an event—our focus is on this “forgotten majority.”
Research indicates that the inflammatory processes leading to plaque rupture and thrombosis are associated with certain bacterial pathogens, notably Porphyromonas gingivalis, found in atherosclerotic plaques. This insight is foundational to our work as we explore innovative methods to target these pathogens and reduce inflammation-driven cardiovascular events.
Approach
1. Identifying intracellular pathogens in tissues from atherosclerosis patients.
2. Setting up a high-throughput screening (HTS) system to test inhibitors of intracellular pathogens.
3. Develop in vitro systems to evaluate effective agents from drug and chemical libraries.
4. Identifying novel antimicrobial drugs specific to intracellular pathogens.
5. Efficacy of the identified compounds was tested in an animal model, demonstrating a significant reduction in atherosclerotic plaques.
6. Filing a patent to protect our discoveries.
Pipeline
1
In a groundbreaking development, we have already found several compounds that can inhibit intracellular P. gingivalis. This pathogen is known to be present in atherosclerotic plaques from patients and also to exacerbate the atherosclerotic plaque formation.
2
Moreover, we have confirmed the identified compounds significantly reduce plaques in an animal model of atherosclerosis.
3
Interestingly, one of the identified compounds has already been approved by the FDA.
4
Finally, we have identified a number of compounds that may be a subject of further pharmacological development.
5
In addition, we have discovered compounds that inhibit P. gingivalis in a biofilm, opening the opportunity to control another chronic inflammation, periodontitis.
We are
Operators. Scientists. Dealmakers. The A-Team for Atherosclerosis
George Dimov
Chairman of Board
Built a $20M+ advisory firm;
brings operational
discipline, financial strategy,
and regulatory insight to
biotech execution.
Emil Kozarov, PhD
Co-founder & Exec. Chairman
Pioneered infection–
atherosclerosis research at
Columbia for 25 yrs, funded
by NIH, AHA. Authored 50+
papers, cited over 2,500 times.
Vadim Mett, PhD
Co-founder & CSO
Expert in developing and
producing advanced therapies
for infectious diseases,
including vaccines and
monoclonal antibodies.
Gaurav Vij (Vik)
CEO & Board Member
Senior biopharma executive with
15+ years in corporate development
and licensing.
Led $15B+ M&A and $10B+
global partnering deals
Frequently Asked Question
What is the focus of Magnacor Therapeutics’ research?
Magnacor is dedicated to developing a novel class of drugs that target atherosclerosis and other chronic inflammatory diseases. Our research specifically addresses cardiovascular disease, aiming to provide therapies for patients with critical unmet medical needs.
What stage is Magnacor Therapeutics in its research and development process?
We have successfully completed animal trials that showed promising results in reducing atherosclerotic plaques. Currently, we are preparing for human trials to further test our therapies with the goal of bringing life-changing treatments to patients worldwide.
How is your approach to cardiovascular disease treatment different?
Our approach focuses on addressing bacterial pathogens associated with atherosclerotic plaques, a factor largely overlooked in traditional treatments. By targeting these intracellular pathogens, we aim to reduce inflammation and atherosclerotic plaque formation, providing a more comprehensive solution to cardiovascular disease.
How can I get involved with Magnacor Therapeutics’ mission?
We welcome interest from potential investors, collaborators, and partners who are passionate about advancing cardiovascular care. Reach out via our Contact Us page to explore opportunities for investment, licensing, or collaboration.